for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akebia Therapeutics Inc

AKBA.OQ

Latest Trade

4.52USD

Change

-0.09(-1.95%)

Volume

152,381

Today's Range

4.43

 - 

4.72

52 Week Range

3.51

 - 

10.44

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.61
Open
4.58
Volume
152,381
3M AVG Volume
21.00
Today's High
4.72
Today's Low
4.43
52 Week High
10.44
52 Week Low
3.51
Shares Out (MIL)
118.86
Market Cap (MIL)
547.96
Forward P/E
-2.31
Dividend (Yield %)
--

Next Event

Akebia Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Akebia Therapeutics Reports Q2 Loss Per Share $0.49

Akebia Therapeutics Announces Settlement Of Auryxia Patent Litigation With Par Pharmaceutical

Akebia Therapeutics Reports Q1 Loss Per Share Of $0.62

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Industry

Biotechnology & Drugs

Contact Info

245 1st St

+1.617.8712098

https://akebia.com/

Executive Leadership

Adrian Adams

Independent Chairman of the Board

John P. Butler

President, Chief Executive Officer, Director

Jason A. Amello

Chief Financial Officer, Senior Vice President, Treasurer

Nicole R. Hadas

Senior Vice President, Chief Legal Officer and Secretary

Steven K. Burke

Senior Vice President, Chief Medical Officer

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.2K

2018

0.2K

2019(E)

0.4K
EPS (USD)

2016

-3.600

2017

-1.770

2018

-1.540

2019(E)

-2.000
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.91
Price To Book (MRQ)
1.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-48.84
Return on Equity (TTM)
-35.03

Latest News

Ex-Akebia employee jailed for night as insider trading trial starts

A former Akebia Therapeutics Inc <AKBA.O> employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

BRIEF-Akebia Therapeutics Reports Q1 Loss Per Share $0.48

* AKEBIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Akebia Therapeutics Announces Proposed Public Offering Of Common Stock

* AKEBIA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Akebia Therapeutics Inc Files For Potential Mixed Shelf Offering Amount Not Disclosed - SEC Filing

* AKEBIA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; AMOUNT NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2tG5aJJ) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Akebia Therapeutics Announces Q4 Earnings Per Share $0.25

* AKEBIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program

* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results

BRIEF-Invirsa secures seed financing to develop new approach

* Invirsa secures seed financing to develop new approach to treating common infectious diseases that affect millions annually Source text for Eikon: Further company coverage:

Insider trading suspect out of U.S. jail as judge weighs 'Jekyll & Hyde' risk

A former Akebia Therapeutics Inc employee accused of insider trading was released from jail on Thursday despite a judge's concern that the man's "Dr. Jekyll and Mr. Hyde" tendencies could lead him to violate his bail conditions.

Ex-Akebia employee suspected of insider trading re-arrested

A former Akebia Therapeutics Inc <AKBA.O> employee accused of insider trading was re-arrested on Friday after violating a bail condition as a prosecutor who once called him "increasingly unhinged" said he would seek the man's detention pending trial.

Ex-Akebia employee faces losing bail in insider trading case

A former Akebia Therapeutics Inc <AKBA.O> employee accused of insider trading faced the growing possibility of having his bail revoked as a U.S. prosecutor argued on Thursday that he posed a flight risk and was growing "increasingly unhinged."

BRIEF-Muneer Satter reports 6.48 pct stake in Akebia Therapeutics

* Muneer Satter reports 6.48 percent stake in Akebia Therapeutics Inc as of July 5 - SEC filing

BRIEF-Akebia Therapeutics announces proposed public offering of common stock

* Akebia Therapeutics announces proposed public offering of common stock

BRIEF-Akebia Therapeutics names Rita Jain as chief medical officer

* Akebia Therapeutics names Rita Jain, M.D. as chief medical officer Source text for Eikon: Further company coverage:

BRIEF-Akebia initiates Phase 2 forward study of Vadadustat

* Akebia initiates Phase 2 forward study of vadadustat in dialysis patients with anemia related to chronic kidney disease hyporesponsive to treatment with erythropoiesis-stimulating agents Source text for Eikon: Further company coverage:

BRIEF-Vifor Pharma reports 8.4 pct stake in Akebia Therapeutics

* Vifor Pharma Ltd reports a 8.4 percent stake in Akebia Therapeutics Inc as of May 12, 2017 - sec filing Source text - http://bit.ly/2q4eS6w Further company coverage:

BRIEF-Akebia and Vifor Pharma announce license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

* Akebia and Vifor Pharma announce exclusive license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

BRIEF-Akebia Therapeutics enters into a license agreement with Otsuka Pharmaceutical

* Says entered into a collaboration and license agreement ( 'agreement') with Otsuka Pharmaceutical Co Ltd Source text:(http://bit.ly/2q40fPR) Further company coverage:

BRIEF-Akebia announces publication of phase 2A results for Vadadustat in patients with anemia related to chronic kidney disease

* Akebia Therapeutics Inc - Akebia announces publication of phase 2A results for Vadadustat in patients with anemia related to chronic kidney disease

BRIEF-Akebia Therapeutics Q4 loss per share $0.99

* Akebia announces fourth quarter and full-year 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up